These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33899789)

  • 1. Cytoplasmic Pattern p53 Immunoexpression in Pelvic and Endometrial Carcinomas With TP53 Mutation Involving Nuclear Localization Domains: An Uncommon But Potential Diagnostic Pitfall With Clinical Implications.
    Rabban JT; Garg K; Ladwig NR; Zaloudek CJ; Devine WP
    Am J Surg Pathol; 2021 Nov; 45(11):1441-1451. PubMed ID: 33899789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.
    Matsumoto N; Manrai P; Rottmann D; Wu X; Assem H; Hui P; Buza N
    Int J Gynecol Pathol; 2023 Nov; 42(6):567-575. PubMed ID: 36730675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
    Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ
    Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
    Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM
    J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Na K; Sung JY; Kim HS
    Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.
    Köbel M; Ronnett BM; Singh N; Soslow RA; Gilks CB; McCluggage WG
    Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S123-S131. PubMed ID: 29517499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
    Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
    Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
    Köbel M; Kang EY
    Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
    Fadare O; Parkash V
    Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
    Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
    Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does a p53 "Wild-type" Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?
    Fadare O; Roma AA; Parkash V; Zheng W; Walavalkar V
    Adv Anat Pathol; 2018 Jan; 25(1):61-70. PubMed ID: 28945609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
    Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
    Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Variation in p53 Usage for Endometrial Carcinoma Diagnosis: Implications for Molecular Subtyping.
    Baniak N; Gilks CB; DeCoteau J; Kinloch M
    Int J Gynecol Pathol; 2020 Nov; 39(6):514-521. PubMed ID: 31569187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic and Genomic Analysis of
    Momeni-Boroujeni A; Dahoud W; Vanderbilt CM; Chiang S; Murali R; Rios-Doria EV; Alektiar KM; Aghajanian C; Abu-Rustum NR; Ladanyi M; Ellenson LH; Weigelt B; Soslow RA
    Clin Cancer Res; 2021 May; 27(9):2613-2623. PubMed ID: 33602681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic P53 Immunostaining With N-Terminus P53 Antibody And Absence Of Staining With C-Terminus P53 Antibody: A Report Of Two Pediatric Sarcomas With Distal Truncating
    Mirbaha H; Carrillo D; Mitui M; Hiemenz MC; Singh V; Rakheja D
    Int J Surg Pathol; 2022 Jun; 30(4):457-461. PubMed ID: 34931562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
    Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
    Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma.
    Jia L; Yuan Z; Wang Y; Cragun JM; Kong B; Zheng W
    Mod Pathol; 2015 Jan; 28(1):118-27. PubMed ID: 24925054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.